

Growing our *understanding* of the global impact of Alzheimer's disease




Alzheimer's disease (AD) is the most common type of dementia,¹ affecting ~50 *million* people worldwide.²

In recent years, our knowledge of AD has grown – we know more now than ever before.³ However, the impact of AD remains significant, and continuous and collaborative research is needed to fully understand this disease.



AD is not a normal part of ageing – it changes who we are.⁴ The exact cause is still unknown, however key characteristics include the build up of specific proteins in the brain, forming clumps called 'plaques' and 'tangles', which gradually kill brain cells.⁵



70% of all risks are linked with genetics,¹⁰ but certain health and lifestyle factors may also increase risk.6 Most cases of AD develop due to a combination of risk factors.⁸

> Symptoms of AD worsen over time, and can affect day-to-day activities. Some impacts are:11,12




- Trouble following a conversation
- Difficulties with writing
- **Disliking social activities**
- **Personality changes**
- Affected sleep cycles

Diagnosis: the increasing importance of biomarkers

AD-associated biological changes may occur 20 + yearsbefore typical symptom onset⁸

An estimated 75% of people living with dementia are undiagnosed14 *Currently, it can take many months* of appointments and multiple tests before AD is diagnosed.¹³





AD biomarkers currently being used to support diagnosis include analysis of cerebrospinal fluid (CSF)15,16



Other AD biomarkers, including blood-based, are under investigation for the diagnosis and management of AD15

A **biomarker** is a *measurable* substance or physical event that correlates with health, disease or drug treatment.¹⁷

Wider use of biomarkers could provide a quicker, cheaper, *non-invasive test for AD – potentially allowing treatment* to start before symptoms do. 15,16

Impact: on society and people's lives



The economic impact of dementia is a growing global challenge and AD is acknowledged to be one of the most expensive diseases; with a cost to individuals and wider society.18

There is a **21%** higher personal spend in direct healthcare costs for people with dementia¹⁸

The cost of dementia increased by 35% from 2010-201918

In the US, 18.5 billion hours of care are provided annually¹⁸

There are intangible costs to people living with AD and their caregivers, largely focused on quality of life, and these are often difficult to measure:18

Emotional stress



- Pain
- Personal relationships
- Use of time

Global collaborations have formed to accelerate the development of diagnostics and treatments for AD, in the order to address this challenge.¹⁸

Hope for the future



Partnerships, new potential treatments and diagnostics are key to our mission to uncover the brain's secrets.

Overcoming this challenge requires close collaboration. Together we must learn, adapt and find solutions to this disease as quickly as possible.

References

- The Alzheimer's Society. Types of dementia. [Internet; cited 2019 Aug 9]. Available from: 1. https://www.alzheimers.org.uk/about-dementia/types-dementia/alzheimers-disease.
- 2. World Health Organization. Dementia. [Internet; cited 2019 Aug 20]. Available from: https://www.who.int/news-room/fact-sheets/detail/dementia.
- Alz Forum. Alzheimer's disease research timeline. [Internet; cited 2019 Aug 9]. Available from: 3. https://www.alzforum.org/timeline/alzheimers-disease.
- The Alzheimer's Society. Normal ageing vs dementia. [Internet; cited 2019 Aug 9]. Available from: 4. https://www.alzheimers.org.uk/about-dementia/symptoms-and-diagnosis/how-dementia-progresses/ normal-ageing-vs-dementia.
- National Institute on Aging. What happens to the brain in alzheimer's disease. [Internet; cited 2019 Aug 9]. 5. Available from: https://www.nia.nih.gov/health/what-happens-brain-alzheimers-disease.
- National Institute on Aging. What causes alzheimer's disease. [Internet; cited 2019 Aug 9]. Available from: 6. https://www.nia.nih.gov/health/what-causes-alzheimers-disease.
- 7. Alzheimer's Research UK. Alzheimer's disease. [Internet; cited 2019 Aug 27]. Available from: https://www.alzheimersresearchuk.org/about-dementia/types-of-dementia/alzheimers-disease/early-onset-alzheimers/.
- Alzheimer's Association. 2019 Alzheimer's disease facts and figures. Alzheimer's Dement. 2019;15(3):321-87. 8.
- Alzheimer's Europe. Familial alzheimer's disease. [Internet; cited 2019 Aug 9]. Available from: 9. https://www.alzheimer-europe.org/Dementia/Other-forms-of-dementia/Neurodegenerative-diseases/ Familial-Alzheimer-s-disease.
- 10. Ballard C, et al. Alzheimer's disease. Lancet. 2011;377:1019-31.
- 11. Alzheimer's Association. 10 Early Signs and Symptoms of Alzheimer's. [Internet; cited 2019 Aug 9]. Available from: https://www.alz.org/alzheimers-dementia/10_signs.
- 12. Alzheimer's Research UK. Symptoms. [Internet; cited 2019 Aug 9]. Available from: https://www.alzheimersresearchuk.org/about-dementia/helpful-information/symptoms/.
- 13. NHS. Alzheimer's disease diagnosis. [Internet; cited 2019 Aug 9]. Available from: https://www.nhs.uk/conditions/alzheimers-disease/diagnosis/.
- 14. Alzheimer's Disease International. 2018 dementia statistics. [Internet; cited 2019, July 30]. Available from: https://www.alz.co.uk/research/statistics.
- 15. Zvěřová M. Alzheimer's disease and blood-based biomarkers potential contexts of use. Neuropsychiatr Dis Treat. 2018;14:1877-1882.
- 16. Alzheimer's Association. Earlier Diagnosis. [Internet; cited 2019, July 30]. Available from: https://www.alz.org/alzheimers-dementia/research progress/earlier-diagnosis.
- 17. Mayeux R. Biomarkers: Potential Uses and Limitations. NeuroRx. 2004;1(2):182-188.
- 18. EI-Hayek YH, Wiley RE, et al. Tip of the iceberg: assessing the global socioeconomic costs of alzheimer's disease and related dementias and strategic implications for stakeholders. J Alzheimers Dis. 2019:70:321-339.

